SCHEMBL4476192

SCHEMBL4476192

C[Si](C)(C)C=C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28230548 0.67
SCHEMBL27476655 0.67
SCHEMBL5539643 0.61
SCHEMBL28396653 0.61
SCHEMBL8679082 0.56
SCHEMBL7053562 0.56
SCHEMBL442087 0.56
SCHEMBL18261219 0.56
Chloromethane SCHEMBL17457033 0.56
SCHEMBL30059 0.56

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346612-A1 INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-11-13 US disclosed
US-20250215019-A1 ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-07-03 US disclosed
CN-119968374-A Cephalotaxine derivatives, pharmaceutical composition, preparation method and application thereof 南开大学 2025-05-09 CN disclosed
WO-2024061357-A1 HARRINGTONINE DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR, AND USE THEREOF 南开大学 2024-03-28 WO disclosed
WO-2023183757-A2 ORTHOGONAL FUNCTIONALIZATION OF BRIDGE-SUBSTITUTED BCPS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-09-28 WO disclosed
US-20220389179-A1 HYDROGEL LIQUID PRECURSOR, METHOD OF MANUFACTURING HYDROGEL FABRICATION PRODUCT, AND HYDROGEL FABRICATION PRODUCT RICOH COMPANY, LTD. (JP) 2022-12-08 US disclosed
EP-4065611-A1 HYDROGEL LIQUID PRECURSOR, METHOD OF MANUFACTURING HYDROGEL FABRICATION PRODUCT, AND HYDROGEL FABRICATION PRODUCT Ricoh Company, Ltd. (JP) 2022-10-05 EP disclosed
WO-2022170218-A1 INTRAMOLECULAR CYCLIZATION FOR GENERAL SYNTHESIS OF BICYCLIC ALKYL BIOISOSTERE BORONATES THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-08-11 WO disclosed
US-10988467-B2 Compounds as ROR gamma modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2021-04-27 US disclosed
EP-3686187-A1 PROCESS FOR THE PREPARATION OF ROR GAMMA MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2020-07-29 EP disclosed
US-7625912-B2 2-Phenylpyrimidinone compounds; anticarcinogenic agents can be synergistically combined with one or more active ingredients such as paclitaxel or trastuzumab; side effect reduction MERCK & CO. INC (US) 2009-12-01 US disclosed
WO-2007146761-A2 DIARYL PYRIMIDINONES AND RELATED COMPOUNDS NEUROGEN CORPORATION (US) 2007-12-21 WO disclosed
US-20070129356-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2007-06-07 US disclosed
US-20070129356-A1 Mitotic kinesin inhibitors MERCK SHARP & DOHME CORP. 2007-06-07 US disclosed
CN-1898215-A Mitotic kinesin inhibitors MERCK & CO INC (US) 2007-01-17 CN disclosed
EP-1697331-A2 MITOTIC KINESIN INHIBITORS Merck & Co., Inc. (US) 2006-09-06 EP disclosed
WO-2005066175-A2 CARBAPENEM INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION GLAXO GROUP LIMITED (GB) 2005-07-21 WO disclosed
WO-2005060654-A2 MITOTIC KINESIN INHIBITORS MERCK & CO., INC. (US) 2005-07-07 WO disclosed
US-6310228-B1 MONOVALENT COPPER IS COORDINATED WITH A BETA-DIKETONE COMPOUND AND AN UNSATURATED HYDROCARBON COMPOUND HAVING A SILYLOXY GROUP MITSUBISHI MATERIALS CORPORATION (JP) 2001-10-30 US disclosed
US-6040465-A Process for producing optically active β-lactones TAKASAGO INTERNATIONAL CORPORATION (JP) 2000-03-21 US disclosed